
|Articles|April 1, 2003
FDA Approves Valacyclovir
San Diego - The U.S. Food and Drug Administration approved a supplemental new drug application for Valtrex (valacyclovir HCl) caplets (Glaxo SmithKline) for the suppression of recurrent genital herpes in HIV-infected individuals. Once daily dosage has been shown to reduce the transmission of symptomatic genital herpes in healthy heterosexual monogamous couples by more than three-quarters, according to Lawrence Corey, M.D.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
4
Phase 2 Nemolizumab Trial Opens for CPUO
5


















